Best Penny Stocks Under $1.00 Right Now

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. While stocks are no longer hitting new all-time highs, the price-to-earnings ratios of most S&P 500 companies still look somewhat expensive historically speaking. Many investors are having trouble finding low-priced stocks that have great business fundamentals and actually generate cash flow.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 20 times their annual earnings. While the stock market is more expensive as a whole than it has been historically, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks, and biotechnology stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 (1 dollar) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

#1 - Unicycive Therapeutics

NASDAQ:UNCY

Stock Price:

$0.51 (+$0.02)

P/E Ratio:

-0.53

Market Cap:

$52.87 million

Average Trading Volume:

1.23 million shares

Consensus Rating:

Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$5.13 (906.1% Upside)

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

#2 - Beyond Air

NASDAQ:XAIR

Stock Price:

$0.49 (-$0.03)

P/E Ratio:

-0.35

Market Cap:

$35.49 million

Average Trading Volume:

545,786 shares

Consensus Rating:

Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$3.67 (645.9% Upside)

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

#3 - Elevation Oncology

NASDAQ:ELEV

Stock Price:

$0.58

P/E Ratio:

-0.71

Market Cap:

$34.35 million

Average Trading Volume:

1.54 million shares

Consensus Rating:

Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$7.80 (1,242.3% Upside)

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

#4 - Gossamer Bio

NASDAQ:GOSS

Stock Price:

$0.70 (-$0.02)

P/E Ratio:

-2.18

Market Cap:

$157.83 million

Average Trading Volume:

1.43 million shares

Consensus Rating:

Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$9.20 (1,220.9% Upside)

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

#5 - Dragonfly Energy

NASDAQ:DFLI

Stock Price:

$0.40 (+$0.03)

P/E Ratio:

-0.88

Market Cap:

$25.06 million

Average Trading Volume:

559,241 shares

Consensus Rating:

Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$1.74 (338.3% Upside)

Dragonfly Energy Holdings Corp. engages in the manufacturing and sale of deep cycle lithium-ion batteries for recreational vehicles, marine vessels, solar and off-grid residence industries, and industrial and energy storage markets. The company provides lithium power systems comprising solar panels, chargers and inverters, system monitoring, alternator regulators, accessories, and others. It also offers battery management systems for monitoring and controlling of battery systems and to protect battery cells from damage in various scenarios. The company provides its products under the Dragonfly Energy, Battle Born, and Wakespeed brand names. Dragonfly Energy Holdings Corp. is headquartered in Reno, Nevada.

#6 - Allurion Technologies

NYSE:ALUR

Stock Price:

$0.45 (+$0.04)

P/E Ratio:

-0.94

Market Cap:

$29.15 million

Average Trading Volume:

726,114 shares

Consensus Rating:

Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$2.88 (534.9% Upside)

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.

#7 - Vor Biopharma

NYSE:VOR

Stock Price:

$0.79 (+$0.03)

P/E Ratio:

-0.48

Market Cap:

$54.58 million

Average Trading Volume:

504,430 shares

Consensus Rating:

Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$11.36 (1,328.9% Upside)

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

#8 - Tempest Therapeutics

NASDAQ:TPST

Stock Price:

$0.90 (+$0.03)

P/E Ratio:

-0.59

Market Cap:

$22.65 million

Average Trading Volume:

2.11 million shares

Consensus Rating:

Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$20.00 (2,126.2% Upside)

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

#9 - Omega Therapeutics

NASDAQ:OMGA

Stock Price:

$0.79 (+$0.03)

P/E Ratio:

-0.59

Market Cap:

$43.75 million

Average Trading Volume:

865,326 shares

Consensus Rating:

Moderate Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$9.20 (1,064.3% Upside)

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

#10 - Oatly Group

NASDAQ:OTLY

Stock Price:

$0.67 (+$0.02)

P/E Ratio:

-0.96

Market Cap:

$395.77 million

Average Trading Volume:

1.98 million shares

Consensus Rating:

Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$1.27 (90.4% Upside)

Oatly Group AB, an oatmilk company, provides a range of plant-based dairy products made from oats in Europe, the Middle East, Africa, the Americas, and Asia. It offers Barista edition oatmilk, oatgurts, frozen desserts, ice-creams, and yogurts; cooking products, including cooking cream, in regular and organic, Crème Fraiche, whipping cream, vanilla custard, and spreads in a variety of flavors; and ready-to-go drinks. The company was formerly known as Havre Global AB and changed its name to Oatly Group AB in March 2021. Oatly Group AB was founded in 1994 and is headquartered in Malmö, Sweden.

#11 - Canoo

NASDAQ:GOEV

Stock Price:

$0.48 (+$0.01)

P/E Ratio:

-0.14

Market Cap:

$39.26 million

Average Trading Volume:

5.39 million shares

Consensus Rating:

Moderate Buy (5 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$22.71 (4,631.9% Upside)

Canoo Inc., a mobility technology company, designs, develops, markets, and manufactures electric vehicles for consumer, commercial fleet, government, and military customers in the United States. the company utilizes its multi-purpose platform architecture, a self-contained, fully functional rolling chassis that directly houses the critical components for operation of an electric vehicle, including its in-house designed proprietary electric drivetrain, battery systems, advanced vehicle control electronics and software, and other critical components. It offers lifestyle delivery vehicles, lifestyle vehicles, multi-purpose delivery vehicles, and pickups; battery modules; and engineering services. In addition, the company provides digital ecosystem, a suite of products and software tools comprising CanooHub, a web-based fleet management portal; driver mobile app for real-time vehicle status and access to remote commands; vehicle human machine interface that encompasses vehicle controls, customizable settings, range mode, cruise control, vehicle alerts, camera feeds for safety and connectivity, such as cellular, Wi-Fi and Bluetooth, as well as data and analytics infrastructure. Canoo Inc. was founded in 2017 and is headquartered in Torrance, California.

#12 - Cognition Therapeutics

NASDAQ:CGTX

Stock Price:

$0.44

P/E Ratio:

-0.45

Market Cap:

$18.28 million

Average Trading Volume:

493,142 shares

Consensus Rating:

Moderate Buy (4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$8.00 (1,718.2% Upside)

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

#13 - Wag! Group

NASDAQ:PET

Stock Price:

$0.21 (+$0.04)

P/E Ratio:

-0.54

Market Cap:

$10.46 million

Average Trading Volume:

346,956 shares

Consensus Rating:

Moderate Buy (4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$4.40 (1,994.2% Upside)

Wag! Group Co. develops and supports a proprietary marketplace technology platform available as a website and mobile app that enables independent pet caregivers to connect with pet parents. Its platform allows pet parents, who require specific pet care services, such as dog walking, pet sitting and boarding, advice from licensed pet experts, home visits, training, and pet insurance comparison tools. The company was founded in 2014 and is headquartered in San Francisco, California.

#14 - Rallybio

NASDAQ:RLYB

Stock Price:

$0.99 (+$0.03)

P/E Ratio:

-0.62

Market Cap:

$41.24 million

Average Trading Volume:

562,112 shares

Consensus Rating:

Moderate Buy (4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$9.75 (880.8% Upside)

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

#15 - Precigen

NASDAQ:PGEN

Stock Price:

$0.84 (+$0.04)

P/E Ratio:

-1.52

Market Cap:

$245.04 million

Average Trading Volume:

952,799 shares

Consensus Rating:

Moderate Buy (4 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings)

Consensus Price Target:

$7.00 (736.6% Upside)

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

#16 - Purple Innovation

NASDAQ:PRPL

Stock Price:

$0.83 (-$0.02)

P/E Ratio:

-0.83

Market Cap:

$89.26 million

Average Trading Volume:

538,678 shares

Consensus Rating:

Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$2.53 (204.7% Upside)

Purple Innovation, Inc. designs and manufactures sleep and other products in the United States and internationally. The company offers mattresses, pillows, cushions, bases, sheets, platforms, adjustable bases, mattress protectors, foundations, blankets, duvets, duvet covers, seat cushions, and pet beds under the Purple brand. It markets and sells its products through its e-commerce online channels, retail brick-and-mortar wholesale partners, third-party online retailers, and Purple showrooms, as well as through its website, Purple.com. The company was founded in 2010 and is headquartered in Lehi, Utah.

#17 - Outset Medical

NASDAQ:OM

Stock Price:

$0.73 (-$0.02)

P/E Ratio:

-0.26

Market Cap:

$38.13 million

Average Trading Volume:

1.34 million shares

Consensus Rating:

Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$4.70 (547.7% Upside)

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

#18 - CytomX Therapeutics

NASDAQ:CTMX

Stock Price:

$0.87 (-$0.02)

P/E Ratio:

5.12

Market Cap:

$68.09 million

Average Trading Volume:

2.51 million shares

Consensus Rating:

Moderate Buy (3 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$5.77 (563.4% Upside)

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

#19 - Innoviz Technologies

NASDAQ:INVZ

Stock Price:

$0.52 (-$0.02)

P/E Ratio:

-0.82

Market Cap:

$71.24 million

Average Trading Volume:

2.06 million shares

Consensus Rating:

Hold (2 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$3.80 (626.4% Upside)

Innoviz Technologies Ltd. manufactures and sells automotive grade LiDAR sensors and perception software to enable safe autonomous driving at a mass scale. The company offers InnovizOne, a solid-state LiDAR sensor designed for automakers and robotaxis, shuttles, trucks, and delivery companies requiring an automotive-grade and mass-producible solution to achieve autonomy. It also provides InnovizTwo, an automotive-grade LiDAR sensor that offers a solution for all levels of autonomous driving, as well as an option to integrate the perception application in the LiDAR sensor; and perception application, a software application that raw point cloud data from Innoviz LiDAR products into perception outputs. The company operates in Europe, Asia Pacific, the Middle East, Africa, and North America. It markets and sells its products through a direct sales organization, as well as through distribution channels. The company is headquartered in Rosh Haayin, Israel.

#20 - Marinus Pharmaceuticals

NASDAQ:MRNS

Stock Price:

$0.31

P/E Ratio:

-0.13

Market Cap:

$17.05 million

Average Trading Volume:

1.58 million shares

Consensus Rating:

Hold (3 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$4.79 (1,448.8% Upside)

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

#21 - FTC Solar

NASDAQ:FTCI

Stock Price:

$0.40

P/E Ratio:

-1.05

Market Cap:

$51.11 million

Average Trading Volume:

2.52 million shares

Consensus Rating:

Hold (2 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$0.85 (112.5% Upside)

FTC Solar, Inc. engages in the provision of solar tracker systems, software, and engineering services in the United States, Asia, Europe, the Middle East, North Africa, South Africa, and Australia. The company offers a self-powered, two-panel in-portrait, and single-axis tracker solution under the Voyager brand name; and a one module-in-portrait solar tracker solution under the Pioneer brand name. Its customers include project developers and solar asset owners, as well as engineering, procurement, and construction contractors that design and build solar energy projects. The company was incorporated in 2017 and is headquartered in Austin, Texas.

#22 - Lion Electric

NYSE:LEV

Stock Price:

$0.19 (-$0.05)

P/E Ratio:

-0.32

Market Cap:

$42.53 million

Average Trading Volume:

435,096 shares

Consensus Rating:

Hold (2 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$1.46 (678.9% Upside)

The Lion Electric Company designs, develops, manufactures, and distributes purpose-built all-electric medium and heavy-duty urban vehicles in North America. The company's products include battery systems, chassis, bus bodies, and truck cabins. It distributes truck and bus parts, as well as accessories. The company was incorporated in 2008 and is based in Saint-Jérôme, Canada.

#23 - WW International

NASDAQ:WW

Stock Price:

$0.95 (+$0.07)

P/E Ratio:

-0.16

Market Cap:

$70.28 million

Average Trading Volume:

5.62 million shares

Consensus Rating:

Hold (3 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)

Consensus Price Target:

$4.50 (373.7% Upside)

WW International, Inc. provides weight management products and services worldwide. It offers a range of nutritional, activity, behavioral, and lifestyle tools and approaches products and services. The company also provides various digital subscription products to wellness and weight management business, which provide interactive and personalized resources that allow users to follow its weight management program through its app and web-based platform; and allows members to inspire and support each other by sharing their experiences with other people on weight health journeys. In addition, it licenses its trademarks and other intellectual property in food, beverages, and other relevant consumer products and services, as well as provides publishing services. The company was formerly known as Weight Watchers International, Inc. and changed its name to WW International, Inc. in September 2019. WW International, Inc. was founded in 1961 and is headquartered in New York, New York.

#24 - Verrica Pharmaceuticals

NASDAQ:VRCA

Stock Price:

$0.89

P/E Ratio:

-0.48

Market Cap:

$40.47 million

Average Trading Volume:

465,867 shares

Consensus Rating:

Hold (2 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$9.60 (981.8% Upside)

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

#25 - Spruce Biosciences

NASDAQ:SPRB

Stock Price:

$0.49

P/E Ratio:

-0.52

Market Cap:

$20.24 million

Average Trading Volume:

681,166 shares

Consensus Rating:

Hold (2 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings)

Consensus Price Target:

$4.00 (716.3% Upside)

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Ideas from MarketBeat

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.